证券代码：002612 证券简称：朗姿股份 公告编号：2025-043 朗姿股份有限公司 关于召开 2025 年第一次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 朗姿股份有限公司（以下简称"公司"）于 2025 年 8 月 1 日召开第五届董事 会第三十二次会议，审议通过了《关于召开公司 2025 年第一次临时股东大会的 议案》。本次股东大会审议的议案具体内容已披露在《证券时报》《上海证券报》 《中国证券报》和巨潮资讯网（www.cninfo.com.cn）。 一、召开会议的基本情况 1、股东大会届次：2025年第一次临时股东大会。 2、股东大会的召集人：本次股东大会由公司董事会召集，经公司第五届董事 会第三十二次会议审议决定召开。 3、会议召开的合法、合规性：本次股东大会会议的召开符合有关法律、行政 法规、部门规章、规范性文件和公司章程的规定。 4、会议召开的日期、时间： 现场会议召开时间：2025年8月18日下午14:00。 网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时间为 2025年8月18日9:15-9:25，9 ...

证券代码：002612 证券简称：朗姿股份 公告编号：2025-041 朗姿股份有限公司 第五届董事会第三十二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 朗姿股份有限公司（以下简称"公司"或"朗姿股份"）第五届董事会第三十二 次会议通知于 2025 年 7 月 28 日以邮件、专人送达等通知方式发出，经 5 位董事 一致同意，于 2025 年 8 月 1 日以通讯及现场会议方式召开。会议由董事长申东 日先生主持，会议应出席董事 5 人，实际出席 5 人。公司监事会及高级管理人员 列席了本次会议。本次会议的召开符合《中华人民共和国公司法》《朗姿股份有 限公司章程》《朗姿股份有限公司董事会议事规则》的有关规定，合法有效。 二、董事会会议审议情况 1、审议并通过了《关于修订<公司章程>及其附件的议案》 为全面贯彻落实最新颁布实施的《中华人民共和国公司法（2023年修订）》 《上市公司章程指引（2025年修订）》《深圳证券交易所股票上市规则（2025年 修订）》《深圳证券交易所上市公司自律监管指引第 1 号 —— 主板上市公 ...

一、关于接受关联方担保的情况概述 为满足日常经营和业务发展资金需要，朗姿股份有限公司（以下简称"公司"或"朗姿股份"）分别向交通 银行股份有限公司北京自贸试验区国际商务服务片区支行（以下简称"交通银行"）和中国邮政储蓄银行 股份有限公司北京顺义区支行（以下简称"邮储银行"）申请流动资金借款人民币10,000万元和1,000万 元，公司控股股东、实际控制人申东日先生及其配偶翁洁女士为公司本次分别向交通银行和邮储银行借 款提供保证担保。 登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 公司控股股东、实际控制人申东日先生及其配偶翁洁女士为公司本次分别向交通银行和邮储银行借款提 供保证担保，该担保不向公司收取任何担保费用，也不需要公司提供反担保。 二、被担保人基本情况 朗姿股份 法定代表人：申东日 注册资本：442,445,375元人民币 成立日期：2006年11月09日 注册地址：北京市顺义区马坡镇白马路63号 经营范围：一般项目：服装服饰零售；服饰研发；服饰制造；服装服饰批发；服装、服饰检验、整理服 务；服装辅料销 ...

北京商报讯（记者 张君花）7月31日，朗姿股份发布公告称，公司分别向交通银行股份有限公司北京自 贸试验区国际商务服务片区支行和中国邮政储蓄银行股份有限公司北京顺义区支行申请流动资金借款1 亿元和1000万元。公司控股股东、实际控制人申东日及其配偶翁洁为公司本次分别向交通银行和邮储银 行借款提供保证担保。 ...

证券代码：002612 证券简称：朗姿股份 公告编号：2025-040 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、关于接受关联方担保的情况概述 为满足日常经营和业务发展资金需要，朗姿股份有限公司（以下简称"公司" 或"朗姿股份"）分别向交通银行股份有限公司北京自贸试验区国际商务服务片区 支行（以下简称"交通银行"）和中国邮政储蓄银行股份有限公司北京顺义区支行 （以下简称"邮储银行"）申请流动资金借款人民币 10,000 万元和 1,000 万元，公 司控股股东、实际控制人申东日先生及其配偶翁洁女士为公司本次分别向交通银 行和邮储银行借款提供保证担保。 公司控股股东、实际控制人申东日先生及其配偶翁洁女士为公司本次分别向 交通银行和邮储银行借款提供保证担保，该担保不向公司收取任何担保费用，也 不需要公司提供反担保。 二、被担保人基本情况 朗姿股份有限公司 关于接受关联方担保的公告 朗姿股份 法定代表人：申东日 注册资本：442,445,375 元人民币 成立日期：2006 年 11 月 09 日 注册地址：北京市顺义区马坡镇白马路 63 号 经营范围：一 ...

Group 1 - As of July 29, there are 5,817 listed companies in the A-share market, with a total remuneration for company secretaries reaching 4.086 billion yuan and an average salary of 754,300 yuan [1] - In the textile and apparel industry, the highest annual salary for a company secretary is 2.3533 million yuan, while the lowest is 128,400 yuan, with an industry average salary of 750,000 yuan [1] - The company secretary with the highest salary in 2024 is Wang Qinglin from Taiping Bird, earning 2.3533 million yuan, while the lowest is Hu Liping from Ruibeka at only 128,400 yuan [1] Group 2 - Most listed companies have increased the salaries of their company secretaries, with the largest increase seen in Zhang Wangwang from Jian Sheng Group, whose salary rose from 430,500 yuan in 2023 to 1.1508 million yuan, a year-on-year increase of 167% [4] - The oldest company secretary in the textile industry is Wang Jianyou from Langzi Co., born in 1963, while the youngest is Cai Xiaoli from Huijie Co., born in 1993, making her only 32 years old [4] - The overall educational background of company secretaries in the industry shows that most hold a bachelor's degree, with only a few having an associate degree, and one, Wang Jianyou, holding a doctoral degree [4] Group 3 - The professional capabilities and performance of company secretaries significantly impact company stock prices, with companies paying over 1 million yuan in salaries experiencing stock price declines [5] - Taiping Bird's stock price has consistently decreased from 2021 to 2024, with annual changes of -5.55%, -31.88%, -6.54%, and -10.12% [5] - Similarly, Dongmei Co. has also seen a continuous decline in stock prices from 2021 to 2024, with annual changes of -21.89%, -32.43%, -10.26%, and -7.41% [5]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、关于接受关联方担保的情况概述 证券代码：002612 证券简称：朗姿股份 公告编号：2025-039 朗姿股份有限公司 关于接受关联方担保的公告 成立日期：2006 年 11 月 09 日 注册地址：北京市顺义区马坡镇白马路 63 号 经营范围：一般项目：服装服饰零售；服饰研发；服饰制造；服装服饰批发； 服装、服饰检验、整理服务；服装辅料销售；互联网销售（除销售需要许可的商 品）；服装辅料制造；服装制造；针纺织品及原料销售；鞋帽批发；鞋帽零售； 母婴用品销售；劳动保护用品生产；劳动保护用品销售；珠宝首饰制造；珠宝首 饰批发；珠宝首饰零售；会议及展览服务；企业管理；企业管理咨询；信息咨询 服务（不含许可类信息咨询服务）；信息技术咨询服务；技术服务、技术开发、 技术咨询、技术交流、技术转让、技术推广；五金产品制造；五金产品批发；五 金产品研发；五金产品零售；玩具制造；玩具销售；皮革制品制造；皮革制品销 售；皮革、毛皮及其制品加工专用设备制造；皮革、毛皮及其制品加工专用设备 销售；箱包制造；箱包销售；日用品批发；日 ...

Group 1 - The medical beauty market in China is experiencing continuous growth, with the number of compliant specialized medical beauty institutions reaching 19,880 in the first half of 2024, an increase of 1,296 institutions or 7% from January 2024 [1][3] - The increase in compliant medical beauty institutions is driven by enhanced regulatory oversight and a growing consumer demand for legitimate medical beauty services [1][3] Group 2 - There is a significant shortage of compliant medical beauty doctors, with an estimated gap of around 20,000 qualified professionals, while the total number of medical beauty practitioners is approximately 1.02 million [4] - The annual growth rate of medical beauty practitioners is around 10%, but the supply of qualified professionals is only increasing at a rate of 5%-8%, highlighting a supply-demand imbalance [4] Group 3 - The distribution of medical beauty positions in China shows a clear imbalance, with only 10% of positions being medical technical roles, which require solid medical knowledge and qualifications [6] - Over 60% of positions are in marketing and operations, which are crucial for attracting customers and driving business growth, but this focus may compromise the quality of medical services [6] Group 4 - The educational requirements for core positions in the medical beauty industry are increasing, with a trend towards higher educational qualifications among professionals [9] - Large medical beauty companies are setting stricter educational standards, with some requiring a full-time bachelor's degree for medical technical roles [9] Group 5 - The distribution of medical beauty talent in China shows a pattern of concentration in eastern regions and high-tier cities, with first-tier cities holding over 50% of medical beauty positions [10] - New first-tier cities are competing for mid-level talent through differentiated strategies, while lower-tier cities struggle due to a lack of local training capabilities [10]

Investment Rating - The report maintains a "Positive" outlook on the cosmetics and medical beauty industry, highlighting the strong performance of domestic brands amid stricter regulations [1]. Core Insights - The cosmetics and medical beauty sector outperformed the market, with the Shenwan Beauty Care Index rising by 5.4% from July 18 to July 25, 2025, surpassing the Shenwan A Index by 1.2 percentage points [5][6]. - Stricter advertising regulations are expected to benefit leading domestic brands, as new rules will increase operational barriers and allow market share to concentrate among top players [11]. - The report emphasizes the importance of new product launches as brands prepare for the competitive landscape in the second half of 2025 [11]. Summary by Sections Industry Performance - The Shenwan Cosmetics Index increased by 3.4%, outperforming the Shenwan A Index by 1.2 percentage points, while the Shenwan Personal Care Index rose by 7.7%, exceeding the Shenwan A Index by 5.5 percentage points [5][6]. Key Company Highlights - Lin Qingxuan, a high-end domestic skincare brand, saw revenue grow from 690 million yuan in 2022 to 1.21 billion yuan in 2024, with net profit turning from a loss of 6 million yuan to a profit of 187 million yuan [17]. - The company has a diverse product matrix with 188 SKUs, a robust supply chain with an annual production capacity of 40 million units, and a comprehensive OMO channel strategy [19]. Market Trends - The report notes a shift in the cosmetics market from quantity to quality, with e-commerce sales expected to account for 47% of total cosmetics sales by 2024, up from 22% in 2016 [13]. - The domestic market is witnessing a rise in local brands, with significant market share gains, particularly in the skincare segment [37]. Investment Recommendations - The report recommends several companies based on their market positioning and growth potential, including Up Beauty, Proya, and Marubi, while suggesting to pay attention to Shanghai Jahwa, Betaini, and Huaxi Biological [5].

Core Viewpoint - Langzi Co., Ltd. relies on capital-driven growth and rapid mergers and acquisitions to form a chain scale, neglecting the core of the medical beauty industry, which is "doctors and services" [1][30]. Financial Performance - Langzi Co., Ltd. reported a projected net profit of 220 million to 260 million yuan for the first half of 2025, representing a year-on-year growth of 31.74% to 55.69% [3][4]. - However, after excluding a 160 million yuan investment gain from the sale of Ruoyuchen, the actual operating net profit dropped to 90 million to 130 million yuan, a decline of 35.68% to 7.09% year-on-year [6][4]. - The first quarter of 2025 showed a decline in revenue, net profit, and cash flow from operating activities, indicating a downward trend [6][7]. Medical Aesthetics Business Challenges - The medical aesthetics segment, which was expected to be a new growth engine, has underperformed, with revenue and gross profit decreasing by 9.22% and 8.58% respectively in Q1 2025 [11][8]. - The gross profit margin of the medical aesthetics business is 55.05%, significantly lower than the traditional apparel and children's products segments, which have margins of 64.51% and 62.28% respectively [11][8]. - Among the seven medical aesthetics brands under Langzi, only the Jingfu Medical Beauty brand achieved positive growth in Q1 2025, while the other six brands experienced revenue and profit declines [13][11]. Industry Dynamics - The medical aesthetics industry has a complex value structure, with upstream pharmaceutical and equipment manufacturers capturing 50%-70% of the profits, while downstream service providers only retain 10%-25% [16][15]. - Operating a medical aesthetics institution is capital-intensive, requiring significant investment in equipment and facilities, with depreciation periods of 5-10 years [17][16]. - The industry faces increasing competition, with the number of specialized medical aesthetics institutions in China reaching 21,000 in January 2025, an increase of approximately 2,400 from the previous year [21][20]. Strategic Decisions and Market Trends - Despite the challenges, Langzi continues to invest in medical aesthetics, viewing it as a low-resistance entry point into the sector with high valuation potential [23][22]. - The medical aesthetics market in China has seen a compound annual growth rate of over 20% from 2011 to 2019, attracting significant capital investment [24][23]. - Langzi's strategy of rapid acquisitions in the medical aesthetics sector has not translated into sustainable growth, as the industry is moving towards a more decentralized model focused on individual practitioners and boutique institutions [30][29]. Conclusion - The fundamental conflict between capital-driven expansion and the intrinsic nature of the medical aesthetics industry may be the root cause of Langzi's current challenges [31][30].